304 related articles for article (PubMed ID: 10978741)
1. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Adler M; Keller JE; Sheridan RE; Deshpande SS
Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
[TBL] [Abstract][Full Text] [Related]
2. Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin.
Adler M; Macdonald DA; Sellin LC; Parker GW
Toxicon; 1996 Feb; 34(2):237-49. PubMed ID: 8711757
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.
Adler M; Capacio B; Deshpande SS
Toxicon; 2000 Oct; 38(10):1381-8. PubMed ID: 10758273
[TBL] [Abstract][Full Text] [Related]
4. Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C.
Morbiato L; Carli L; Johnson EA; Montecucco C; Molgó J; Rossetto O
Eur J Neurosci; 2007 May; 25(9):2697-704. PubMed ID: 17561839
[TBL] [Abstract][Full Text] [Related]
5. 3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms.
Bradford AB; Machamer JB; Russo TM; McNutt PM
Toxicol Appl Pharmacol; 2018 Feb; 341():77-86. PubMed ID: 29366638
[TBL] [Abstract][Full Text] [Related]
6. Persistence of botulinum neurotoxin action in cultured spinal cord cells.
Keller JE; Neale EA; Oyler G; Adler M
FEBS Lett; 1999 Jul; 456(1):137-42. PubMed ID: 10452545
[TBL] [Abstract][Full Text] [Related]
7. Uptake of botulinum neurotoxin into cultured neurons.
Keller JE; Cai F; Neale EA
Biochemistry; 2004 Jan; 43(2):526-32. PubMed ID: 14717608
[TBL] [Abstract][Full Text] [Related]
8. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A.
Keller JE; Neale EA
J Biol Chem; 2001 Apr; 276(16):13476-82. PubMed ID: 11278807
[TBL] [Abstract][Full Text] [Related]
9. Botulinum neurotoxin serotype D - A potential treatment alternative for BoNT/A and B non-responding patients.
Kutschenko A; Weisemann J; Kollewe K; Fiedler T; Alvermann S; Böselt S; Escher C; Garde N; Gingele S; Kaehler SB; Karatschai R; Krüger THC; Sikorra S; Tacik P; Wegner F; Wollmann J; Bigalke H; Wohlfarth K; Rummel A
Clin Neurophysiol; 2019 Jun; 130(6):1066-1073. PubMed ID: 30871800
[TBL] [Abstract][Full Text] [Related]
10. Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions.
Baskaran P; Lehmann TE; Topchiy E; Thirunavukkarasu N; Cai S; Singh BR; Deshpande S; Thyagarajan B
Toxicon; 2013 Sep; 72():71-80. PubMed ID: 23810945
[TBL] [Abstract][Full Text] [Related]
11. Botulinum Neurotoxins Can Enter Cultured Neurons Independent of Synaptic Vesicle Recycling.
Pellett S; Tepp WH; Scherf JM; Johnson EA
PLoS One; 2015; 10(7):e0133737. PubMed ID: 26207366
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons.
Foran PG; Mohammed N; Lisk GO; Nagwaney S; Lawrence GW; Johnson E; Smith L; Aoki KR; Dolly JO
J Biol Chem; 2003 Jan; 278(2):1363-71. PubMed ID: 12381720
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of neurotransmitter release by peptides that mimic the N-terminal domain of SNAP-25.
Apland JP; Adler M; Oyler GA
J Protein Chem; 2003 Feb; 22(2):147-53. PubMed ID: 12760419
[TBL] [Abstract][Full Text] [Related]
14. Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations.
Adler M; Deshpande SS; Apland JP; Murray B; Borrell A
Neurochem Int; 2012 Nov; 61(6):866-73. PubMed ID: 22841859
[TBL] [Abstract][Full Text] [Related]
15. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system.
Tsai YC; Maditz R; Kuo CL; Fishman PS; Shoemaker CB; Oyler GA; Weissman AM
Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16554-9. PubMed ID: 20823219
[TBL] [Abstract][Full Text] [Related]
16. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis.
Jurasinski CV; Lieth E; Dang Do AN; Schengrund CL
Toxicon; 2001 Sep; 39(9):1309-15. PubMed ID: 11384718
[TBL] [Abstract][Full Text] [Related]
17. Transynaptic Action of Botulinum Neurotoxin Type A at Central Cholinergic Boutons.
Caleo M; Spinelli M; Colosimo F; Matak I; Rossetto O; Lackovic Z; Restani L
J Neurosci; 2018 Nov; 38(48):10329-10337. PubMed ID: 30315128
[TBL] [Abstract][Full Text] [Related]
18. On the action of botulinum neurotoxins A and E at cholinergic terminals.
Washbourne P; Pellizzari R; Rossetto O; Bortoletto N; Tugnoli V; De Grandis D; Eleopra R; Montecucco C
J Physiol Paris; 1998 Apr; 92(2):135-9. PubMed ID: 9782457
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins.
Sharma SK; Singh BR
Biochemistry; 2004 Apr; 43(16):4791-8. PubMed ID: 15096048
[TBL] [Abstract][Full Text] [Related]
20. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
